Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788098 | PMC |
| http://dx.doi.org/10.1016/j.mehy.2022.110774 | DOI Listing |
Publication Analysis
Top Keywords
diethylcarbamazine potential
8
potential treatment
4
treatment covid-19
4
covid-19 lung
4
lung fibrosis
4
fibrosis diethylcarbamazine
4
diethylcarbamazine antiparasitic
4
antiparasitic drug
4
drug possesses
4
possesses anti-inflammatory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!